Business Context and Reporting Period
This Form 8-K is a current report filed by BeiGene, Ltd. on June 8, 2017. The registrant is an emerging growth company incorporated in the Cayman Islands. The filing addresses a corporate governance issue regarding the composition of the Board of Directors and the Audit Committee following the annual general meeting held on June 1, 2017.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance and board composition rather than financial performance.
Material Changes
Ke Tang, a member of the Audit Committee, decided not to stand for re-election at the annual general meeting. Consequently, the Company notified NASDAQ of his departure on June 2, 2017. On June 8, 2017, NASDAQ notified the Company that this resignation resulted in non-compliance with NASDAQ Listing Rule 5605 regarding audit committee requirements.
Outlook, Risks, and Contingencies
The Company intends to appoint a new director to restore compliance with NASDAQ Listing Rule 5605. The cure period is defined as the earlier of the next annual general shareholders' meeting or June 1, 2018. However, if the next annual general shareholders' meeting is held before November 28, 2017, the appointment must be made no later than November 28, 2017.
Key Facts for Investor Verification
- Ke Tang's departure from the Audit Committee triggered a NASDAQ listing compliance issue.
- The Company is currently non-compliant with NASDAQ Listing Rule 5605.
- A new director must be appointed by the earlier of the next annual meeting or June 1, 2018 (with a potential earlier deadline of November 28, 2017).
- No financial data or operational metrics are disclosed in this specific filing.